Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies
Annals of the Rheumatic Diseases · 2026-02 · 85 (2) · 370-378
DOI: 10.1016/j.ard.2025.05.021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of the Rheumatic Diseases, 2026-02. Verfasst von Benjamin A Turturice und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Glucocorticoids, Janus Kinase Inhibitors, Hereditary Autoinflammatory Diseases, Genetic Diseases, X-Linked. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Heart Lung and Blood Institute Division of Intramural Research, National Institutes of Health.
Abstract (Originalsprache)
OBJECTIVES: To establish the long-term impact of cytokine-directed therapies on glucocorticoid use and clinical outcomes in Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS). METHODS: Patients with VEXAS were prospectively followed for events of transfusion dependence, haematopoietic stem cell transplantation or death. Laboratory results, glucocorticoid exposure and clinical measures were retrospectively assessed in relationship to treatment initiation with interleukin-6-directed therapies (anti-IL6R) or Janus kinase inhibitors (JAKi). Patients were stratified by UBA1 variants and presence of typical clonal haematopoiesis with variant allele fraction ≥ 10% (CHVAF≥10%). RESULTS: In 71 VEXAS patients (81.7% with anti-IL6R or JAKi exposure), event-free survival differed by genotype and presence of concomitant CHVAF≥10%: p.M41V (HR [95% confidence interval (CI)]: 5.7 [1.5-20.4]) or p.M41L/T with CHVAF≥10% (hazard ratio [HR]: 5.7 [1.6-20.8]) compared to p.M41L. No association between event rates and exposure to anti-IL6R or JAKi was observed. The p.M41V genotype had the highest risk of anaemia, elevated C-reactive protein (CRP) levels, and monocytopenia. Over a median follow-up of 4.8 (interquartile range [IQR] 3.0, 8.1) years, the patients' mean glucocorticoid dose was >15 mg/day prednisone regardless of variant or disease duration. At prospective visits, clinical remission on ≤10 mg/day prednisone was observed in only 2.7% of visits. Treatment with anti-IL6R or JAKi showed no clinically meaningful reduction (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: peter.grayson@nih.gov.
Förderung
- Intramural NIH HHS
- National Heart Lung and Blood Institute Division of Intramural Research
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Turturice, B. A., Fike, A., Patel, B. A., Groarke, E. M., Gutierrez-Rodriguez, F., Stonick, K., Berrett, H., Liu, S., Darden, I., Quinn, K. A., Young, N. S., & Grayson, P. C. (2026). Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies. Annals of the Rheumatic Diseases, 85(2), 370-378. https://doi.org/10.1016/j.ard.2025.05.021
Vancouver
Turturice BA, Fike A, Patel BA, Groarke EM, Gutierrez-Rodriguez F, Stonick K, et al. Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies. Annals of the Rheumatic Diseases. 2026;85(2):370-378. doi:10.1016/j.ard.2025.05.021
BibTeX
@article{Turturice2026,
author = {Turturice, Benjamin A and Fike, Alice and Patel, Bhavisha A and Groarke, Emma M and Gutierrez-Rodriguez, Fernanda and Stonick, Karyssa and Berrett, Hannah and Liu, Shanni and Darden, Ivana and Quinn, Kaitlin A and Young, Neal S and Grayson, Peter C},
title = {Disease Trajectories and Glucocorticoid Exposure in VEXAS Syndrome Treated with Cytokine-Directed Therapies},
journal = {Annals of the Rheumatic Diseases},
year = {2026},
volume = {85},
number = {2},
pages = {370--378},
doi = {10.1016/j.ard.2025.05.021}
}
EUVIMED